For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Corcept Therapeutics Inc (NASDAQ: CORT) closed at $33.79 down -1.03% from its previous closing price of $34.14. In other words, the price has decreased by -$1.03 from its previous closing price. On the day, 0.91 million shares were traded. CORT stock price reached its highest trading level at $34.51 during the session, while it also had its lowest trading level at $33.77.
Ratios:
For a deeper understanding of Corcept Therapeutics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.46 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 28.64. For the most recent quarter (mrq), Quick Ratio is recorded 5.48 and its Current Ratio is at 5.57. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on November 06, 2023, Upgraded its rating to Buy and sets its target price to $38 from $29 previously.
On April 11, 2023, SVB Securities started tracking the stock assigning a Market Perform rating and target price of $25.
On April 04, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $27.Piper Sandler initiated its Overweight rating on April 04, 2023, with a $27 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 01 ’24 when Swisher Daniel N JR sold 150 shares for $38.50 per share. The transaction valued at 5,775 led to the insider holds 0 shares of the business.
Guyer William sold 10,000 shares of CORT for $386,700 on Aug 01 ’24. The Chief Development Officer now owns 6,039 shares after completing the transaction at $38.67 per share. On Aug 01 ’24, another insider, Swisher Daniel N JR, who serves as the Director of the company, bought 150 shares for $38.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CORT now has a Market Capitalization of 3530784768 and an Enterprise Value of 3063313408. As of this moment, Corcept’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.97, and their Forward P/E ratio for the next fiscal year is 19.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.20 while its Price-to-Book (P/B) ratio in mrq is 5.92. Its current Enterprise Value per Revenue stands at 5.378 whereas that against EBITDA is 23.824.
Stock Price History:
Over the past 52 weeks, CORT has reached a high of $39.75, while it has fallen to a 52-week low of $20.84. The 50-Day Moving Average of the stock is 3.07%, while the 200-Day Moving Average is calculated to be 24.07%.
Shares Statistics:
For the past three months, CORT has traded an average of 1.07M shares per day and 990870 over the past ten days. A total of 103.41M shares are outstanding, with a floating share count of 89.89M. Insiders hold about 13.97% of the company’s shares, while institutions hold 86.99% stake in the company. Shares short for CORT as of 1722384000 were 22263073 with a Short Ratio of 20.85, compared to 1719532800 on 21884969. Therefore, it implies a Short% of Shares Outstanding of 22263073 and a Short% of Float of 29.950001999999998.
Earnings Estimates
The company has 5.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.27, with high estimates of $0.35 and low estimates of $0.2.
Analysts are recommending an EPS of between $1.26 and $1.05 for the fiscal current year, implying an average EPS of $1.11. EPS for the following year is $1.69, with 5.0 analysts recommending between $1.96 and $1.36.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $171.14M this quarter.It ranges from a high estimate of $177.84M to a low estimate of $165.7M. As of the current estimate, Corcept Therapeutics Inc’s year-ago sales were $119.68MFor the next quarter, 5 analysts are estimating revenue of $176.26M. There is a high estimate of $180.1M for the next quarter, whereas the lowest estimate is $170.9M.
A total of 5 analysts have provided revenue estimates for CORT’s current fiscal year. The highest revenue estimate was $668.54M, while the lowest revenue estimate was $647.2M, resulting in an average revenue estimate of $658M. In the same quarter a year ago, actual revenue was $482.38MBased on 5 analysts’ estimates, the company’s revenue will be $778.4M in the next fiscal year. The high estimate is $827.7M and the low estimate is $714.1M.
